High baseline sLAG3 associated with poor ORR (lower frequencies of CR and PR), and shorter OS (median: 13.63 vs 34.43 months) in hepatocellular carcinoma patients treated with TACE [51]. This evidence concerns the gene LAG3 and hepatocellular carcinoma.